A team of scientists from Nanyang Technological University Singapore has developed a new biochip that, when paired with computer vision, can detect quickly and accurately extremely small amounts of microRNAs, which are tiny genetic markers linked to diseases such as heart disease. Published in the scientific journal, the new biosensing platform combines a specially designed nanophotonic chip with AI-automated image analysis. With a tiny drop of blood loaded into the chip, it can rapidly detect multiple microRNA biomarkers. With its integrated AI imaging function, thousands of microRNA signals can be imaged and analysed in a single snapshot. Compared with the current gold standard of detecting microRNA - PCR (polymerase chain reaction) detects tiny amounts of genetic material by copying them many times - the new device can cut detection time from hours to 20 minutes. MicroRNAs are short RNA molecules that help regulate genes that work in the body.

Imagine you have just been diagnosed with early-stage cancer and, before your next appointment, you type a question into an AI chatbot: "Which alternative clinics can successfully treat cancer?" Within seconds you get a polished, footnoted answer that reads like it was written by a doctor. Except some of the claims are unfounded, the footnotes lead nowhere, and the chatbot never once suggests that the question itself might be the wrong one to ask. That scenario is not hypothetical. It is, roughly speaking, what a team of seven researchers found when they put five of the world's most popular chatbots through a systematic health-information stress test. The results are published in BMJ Open .

Missouri is testing medical drones to move blood and lab samples faster as rural patients face longer travel times for care.

This material may not be published, broadcast, rewritten, or redistributed. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset . Powered and implemented by FactSet Digital Solutions . Mutual Fund and ETF data provided by LSEG .

We study semisupervised mean estimation with a small labeled sample, a large unlabeled sample, and a black-box prediction model whose output may be miscalibrated. A standard approach in this setting is augmented inverse-probability weighting (AIPW) [Robins et al., 1994], which protects against prediction-model misspecification but can be inefficient when the prediction score is poorly aligned with the outcome scale. We introduce Calibrated Prediction-Powered Inference, which post-hoc calibrates the prediction score on the labeled sample before using it for semisupervised estimation. This simple step requires no retraining and can improve the original score both as a predictor of the outcome and as a regression adjustment for semisupervised inference. We study both linear and isotonic calibration. For isotonic calibration, we establish first-order optimality guarantees: isotonic post-processing can improve predictive accuracy and estimator efficiency relative to the original score and simpler post-processing rules, while no further post-processing of the fitted isotonic score yields additional first-order gains. For linear calibration, we show first-order equivalence to PPI++. We also clarify the relationship among existing estimators, showing that the original PPI estimator is a special case of AIPW and can be inefficient when the prediction model is accurate, while PPI++ is AIPW with empirical efficiency maximization [Rubin et al., 2008]. In simulations and real-data experiments, our calibrated estimators often outperform PPI and are competitive with, or outperform, AIPW and PPI++. We provide an accompanying Python package, ppi_aipw, at https://larsvanderlaan.github.io/ppi-aipw/.

Michael Dell and Susan Dell became the first donors to give more than $1 billion to the University of Texas at Austin, funding a massive AI-native hospital and research campus.

One of the dominant paradigms in self-supervised learning (SSL), illustrated by MoCo or DINO, aims to produce robust representations by capturing features that are insensitive to certain image transformations such as illumination, or geometric changes. This strategy is appropriate when the objective is to recognize objects independently of their appearance. However, it becomes counterproductive as soon as appearance itself constitutes the discriminative signal. In weather analysis, for example, rain streaks, snow granularity, atmospheric scattering, as well as reflections and halos, are not noise: they carry the essential information. In critical applications such as autonomous driving, ignoring these cues is risky, since grip and visibility depend directly on ground conditions and atmospheric conditions. We introduce ST-STORM, a hybrid SSL framework that treats appearance (style) as a semantic modality to be disentangled from content. Our architecture explicitly separates two latent streams, regulated by gating mechanisms. The Content branch aims at a stable semantic representation through a JEPA scheme coupled with a contrastive objective, promoting invariance to appearance variations. In parallel, the Style branch is constrained to capture appearance signatures (textures, contrasts, scattering) through feature prediction and reconstruction under an adversarial constraint. We evaluate ST-STORM on several tasks, including object classification (ImageNet-1K), fine-grained weather characterization, and melanoma detection (ISIC 2024 Challenge). The results show that the Style branch effectively isolates complex appearance phenomena (F1=97% on Multi-Weather and F1=94% on ISIC 2024 with 10% labeled data), without degrading the semantic performance (F1=80% on ImageNet-1K) of the Content branch, and improves the preservation of critical appearance

Clinical decision-making often involves selecting tests that are costly, invasive, or time-consuming, motivating individualized, sequential strategies for what to measure and when to stop ascertaining. We study the problem of learning cost-optimal sequential decision policies from retrospective data, where test availability depends on prior results, inducing informative missingness. Under a sequential missing-at-random mechanism, we develop a doubly robust Q-learning framework for estimating optimal policies. The method introduces path-specific inverse probability weights that account for heterogeneous test trajectories and satisfy a normalization property conditional on the observed history. By combining these weights with auxiliary contrast models, we construct orthogonal pseudo-outcomes that enable unbiased policy learning when either the acquisition model or the contrast model is correctly specified. We establish oracle inequalities for the stage-wise contrast estimators, along with convergence rates, regret bounds, and misclassification rates for the learned policy. Simulations demonstrate improved cost-adjusted performance over weighted and complete-case baselines, and an application to a prostate cancer cohort study illustrates how the method reduces testing cost without compromising predictive accuracy.

Background: Single-cell RNA sequencing (scRNA-seq) enables gene expression profiling at cellular resolution but is inherently affected by sparsity caused by dropout events, where expressed genes are recorded as zeros due to technical limitations. These artifacts distort gene expression distributions and compromise downstream analyses. Numerous imputation methods have been proposed to recover latent transcriptional signals. These methods range from traditional statistical models to deep learning (DL)-based methods. However, their comparative performance remains unclear, as existing benchmarks evaluate only a limited subset of methods, datasets, and downstream analyses. Results: We present a comprehensive benchmark of 15 scRNA-seq imputation methods spanning 7 methodological categories, including traditional and DL-based methods. Methods are evaluated across 30 datasets from 10 experimental protocols on 6 downstream analyses. Results show that traditional methods, such as model-based, smoothing-based, and low-rank matrix-based methods, generally outperform DL-based methods, including diffusion-based, GAN-based, GNN-based, and autoencoder-based methods. In addition, strong performance in numerical gene expression recovery does not necessarily translate into improved biological interpretability in downstream analyses, including cell clustering, differential expression analysis, marker gene analysis, trajectory analysis, and cell type annotation. Furthermore, method performance varies substantially across datasets, protocols, and downstream analyses, with no single method consistently outperforming others. Conclusions: Our findings provide practical guidance for selecting imputation methods tailored to specific analytical objectives and underscore the importance of task-specific evaluation when assessing imputation performance in scRNA-seq data analysis.

Predicting counterfactual outcomes in longitudinal data, where sequential treatment decisions heavily depend on evolving patient states, is critical yet notoriously challenging due to complex time-dependent confounding and inadequate uncertainty quantification in existing methods. We introduce the Causal Diffusion Model (CDM), the first denoising diffusion probabilistic approach explicitly designed to generate full probabilistic distributions of counterfactual outcomes under sequential interventions. CDM employs a novel residual denoising architecture with relational self-attention, capturing intricate temporal dependencies and multimodal outcome trajectories without requiring explicit adjustments (e.g., inverse-probability weighting or adversarial balancing) for confounding. In rigorous evaluation on a pharmacokinetic-pharmacodynamic tumor-growth simulator widely adopted in prior work, CDM consistently outperforms state-of-the-art longitudinal causal inference methods, achieving a 15-30% relative improvement in distributional accuracy (1-Wasserstein distance) while maintaining competitive or superior point-estimate accuracy (RMSE) under high-confounding regimes. By unifying uncertainty quantification and robust counterfactual prediction in complex, sequentially confounded settings, without tailored deconfounding, CDM offers a flexible, high-impact tool for decision support in medicine, policy evaluation, and other longitudinal domains.